New treatment promises to increase lung cancer survival
By Rob Clancy, staff writer. Reviewed by Associate Professor Daniel Gough
Researchers are tackling the problem of chemoresistance in lung cancer patients with a new treatment, which offers hope of increased lung cancer survival rates.
Associate Professor Dan Gough says lung cancer is the leading cause of cancer related deaths worldwide; small cell lung cancer (SCLC), in particular, is an incredibly lethal form of lung cancer that has a mortality rate of around 95 per cent.
SCLC patients typically respond to front line platinum-based chemotherapy, but almost always relapse with drug resistant disease.
A huge difference to lung cancer survival rates
“That leaves very few treatment options, so anything that can reduce chemoresistance, or effectively treat recurrent disease will make a huge difference to lung cancer survival rates,” he said.
“Our study, published in the Journal of Experimental and Clinical Cancer Research, has identified a new drug that is very effective against relapsed lung cancer offering a new hope to these patients.”
“Our study developed models of resistance and performed drug screening to identify new agents,” A/Prof Gough said.
Doubles lung cancer survival time
“We were able to show that a novel compound Fimepinostat is incredibly effective and indeed it doubles lung cancer survival time.“
Fimepinostat has been used in clinical trials for other cancers, so the way is clear to use it in trials for SCLC.
Initial discussions have been held with the manufacturer of Fimepinostat about clinical trial design for this agent in small cell lung cancer.
“There has been an urgent and unmet need to identify new drugs that will improve the outcome for these patients.”
Journal | Journal of Experimental &Clinical Cancer Research
Title | MYC drives platinum resistant SCLCthat is overcome by the dual PI3K-HDACinhibitor fimepinostat
View publication | https://doi.org/10.1186/s13046-023-02678-1
About Hudson Institute
Hudson Institute’ s research programs deliver in three areas of medical need – inflammation, cancer, women’s and newborn health. More
Hudson News
Get the inside view on discoveries and patient stories
“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”